Design of a compact superconducting accelerator for advanced heavy-ion therapy

Iwata, Y.; Shirai, Tomoyuki; Mizushima, Kota; Matsuba, Shunya; Yang, Yuning; Noda, Etsuo; Urata, Masami; Muramatsu, M.; Katagiri, Ken; Yonai, Shunsuke; Inaniwa, Taku; Sato, Shinji; Abe, Yasushi; Fujimoto, T.; Sasano, Toshinobu; Shiraishi, Tadahiro; Suzuki, Taku; Takahashi, Katsuyuki; Kondo, Ki.; Sakaki, H.; Nishiuchi, Mamiko; Orikasa, Takahiro; Takayama, S.; Amano, Saki; Nakanishi, K.; Tachibana, M.; Touchi, Y.; Tsubomatsu, S.; Nomura, S.

doi:10.1016/j.nima.2023.168312

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, among the indications for helium ion therapy, breast cancer treatment might not be among the first indications to be handled in comparison to others where the sharp helium ion lateral dose penumbra could help in reducing treatment related sequelae, such as in head, head and neck or pediatric tumors. However, with the upcoming novel superconducting cyclotron or synchrotron [67,68], reducing the facility footprint and cost, helium ions could be made more available for clinical practice. For future ion facilities without access to protons [67], the results of this study could provide initial insight into the possibilities of left-sided breast cancer treatments with helium ions.…”

Section: Discussionmentioning

confidence: 99%

“…However, with the upcoming novel superconducting cyclotron or synchrotron [67,68], reducing the facility footprint and cost, helium ions could be made more available for clinical practice. For future ion facilities without access to protons [67], the results of this study could provide initial insight into the possibilities of left-sided breast cancer treatments with helium ions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring Helium Ions’ Potential for Post-Mastectomy Left-Sided Breast Cancer Radiotherapy

Bonaccorsi,

Tessonnier,

Hoeltgen

et al. 2024

Cancers

View full text Add to dashboard Cite

Proton therapy presents a promising modality for treating left-sided breast cancer due to its unique dose distribution. Helium ions provide increased conformality thanks to a reduced lateral scattering. Consequently, the potential clinical benefit of both techniques was explored. An explorative treatment planning study involving ten patients, previously treated with VMAT (Volumetric Modulated Arc Therapy) for 50 Gy in 25 fractions for locally advanced, node-positive breast cancer, was carried out using proton pencil beam therapy with a fixed relative biological effectiveness (RBE) of 1.1 and helium therapy with a variable RBE described by the mMKM (modified microdosimetric kinetic model). Results indicated that target coverage was improved with particle therapy for both the clinical target volume and especially the internal mammary lymph nodes compared to VMAT. Median dose value analysis revealed that proton and helium plans provided lower dose on the left anterior descending artery (LAD), heart, lungs and right breast than VMAT. Notably, helium therapy exhibited improved ipsilateral lung sparing over protons. Employing NTCP models as available in the literature, helium therapy showed a lower probability of grade ≤ 2 radiation pneumonitis (22% for photons, 5% for protons and 2% for helium ions), while both proton and helium ions reduce the probability of major coronary events with respect to VMAT.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Exploring Helium Ions’ Potential for Post-Mastectomy Left-Sided Breast Cancer Radiotherapy

Bonaccorsi,

Tessonnier,

Hoeltgen

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Despite the promising benefits of HRT for conditions such as advanced JNA, its accessibility remains limited, primarily due to the scarcity of treatment centers that are equipped with the necessary technical infrastructure to provide this therapy. However, advancements in cyclotron technology and compact solutions may pave the way for wider implementation of HRT in the future [ 46 , 47 ].…”

Section: Discussionmentioning

confidence: 99%

Helium Ion Therapy for Advanced Juvenile Nasopharyngeal Angiofibroma

Hoeltgen,

Meixner,

Hoegen-Saßmannshausen

et al. 2024

Cancers

View full text Add to dashboard Cite

Helium ion therapy (HRT) is a promising modality for the treatment of pediatric tumors and those located close to critical structures due to the favorable biophysical properties of helium ions. This in silico study aimed to explore the potential benefits of HRT in advanced juvenile nasopharyngeal angiofibroma (JNA) compared to proton therapy (PRT). We assessed 11 consecutive patients previously treated with PRT for JNA in a definitive or postoperative setting with a relative biological effectiveness (RBE) weighted dose of 45 Gy (RBE) in 25 fractions at the Heidelberg Ion-Beam Therapy Center. HRT plans were designed retrospectively for dosimetric comparisons and risk assessments of radiation-induced complications. HRT led to enhanced target coverage in all patients, along with sparing of critical organs at risk, including a reduction in the brain integral dose by approximately 27%. In terms of estimated risks of radiation-induced complications, HRT led to a reduction in ocular toxicity, cataract development, xerostomia, tinnitus, alopecia and delayed recall. Similarly, HRT led to reduced estimated risks of radiation-induced secondary neoplasms, with a mean excess absolute risk reduction of approximately 30% for secondary CNS malignancies. HRT is a promising modality for advanced JNA, with the potential for enhanced sparing of healthy tissue and thus reduced radiation-induced acute and long-term complications.

show abstract